Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
NCT ID: NCT01938833
Last Updated: 2025-05-16
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
9 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-04-30
Study Completion Date
2016-12-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase I/II trial studies the side effects and best dose of romidepsin when given together with paclitaxel albumin-stabilized nanoparticle formulation and to see how well they work in treating patients with metastatic inflammatory breast cancer. Romidepsin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving romidepsin and paclitaxel albumin-stabilized nanoparticle formulation may be an effective treatment for inflammatory breast cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
NCT00331630
Breast Cancer
COMPLETED
EARLY_PHASE1
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
NCT02034916
Breast Neoplasms
BRCA 1 Gene Mutation
BRCA 2 Gene Mutation
TERMINATED
PHASE2
ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer
NCT00110084
Breast Cancer
COMPLETED
PHASE2
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
NCT03130439
Breast Cancer
TERMINATED
PHASE2
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
NCT04498520
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
+32 more
WITHDRAWN
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
1. To assess the safety of the combination of romidepsin plus Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) delivered weekly. (Phase I)
2. To determine the maximum tolerated dose (MTD) of romidepsin with full dose weekly Abraxane to define a recommended phase II doses of the combination. (Phase I)
3. To assess the progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2) negative, newly diagnosed metastatic inflammatory breast cancer treated with the combination of romidepsin and Abraxane. (Phase II)
SECONDARY OBJECTIVES:
1. To assess the safety and tolerability of the combination of romidepsin and Abraxane.
2. To determine the adverse event profile of the combination of romidepsin and Abraxane.
3. To assess the overall response rate (ORR) and clinical benefit rate (CBR) in patients with newly recurrent inflammatory breast cancer (IBC) treated with the combination of romidepsin and Abraxane.
OUTLINE: This is a phase I, dose-escalation study of romidepsin followed by a phase II study.
Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.
1. To assess the safety of the combination of romidepsin plus Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) delivered weekly. (Phase I)
2. To determine the maximum tolerated dose (MTD) of romidepsin with full dose weekly Abraxane to define a recommended phase II doses of the combination. (Phase I)
3. To assess the progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2) negative, newly diagnosed metastatic inflammatory breast cancer treated with the combination of romidepsin and Abraxane. (Phase II)
SECONDARY OBJECTIVES:
1. To assess the safety and tolerability of the combination of romidepsin and Abraxane.
2. To determine the adverse event profile of the combination of romidepsin and Abraxane.
3. To assess the overall response rate (ORR) and clinical benefit rate (CBR) in patients with newly recurrent inflammatory breast cancer (IBC) treated with the combination of romidepsin and Abraxane.
OUTLINE: This is a phase I, dose-escalation study of romidepsin followed by a phase II study.
Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HER2-negative Breast Cancer
Inflammatory Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (Romidepsin and Abraxane)
Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Romidepsin
Intervention Type
DRUG
Abraxane
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Romidepsin
Intervention Type
DRUG
Abraxane
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Istodax
FK228
FR901228
Depsipeptide
Protein-bound paclitaxel
Paclitaxel albumin-stabilized nanoparticle formulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients must have histologically or cytologically confirmed breast carcinoma with a clinical diagnosis of IBC based on the presence of inflammatory changes in the involved breast, such as diffuse erythema and edema (peau d'orange), with or without an underlying palpable mass involving the majority of the skin of the breast. Pathological evidence of dermal lymphatic invasion should be noted but is not required for diagnosis.
2. Patients may have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 as described in detail in section 11.0 or non-measurable tumors
3. Patients must have demonstrated metastatic disease and not received \>2 lines of systemic therapy for metastatic disease
4. Age \> 18 years
5. ECOG performance status 0, 1 or 2
6. Patients must have normal organ and marrow function as defined below: a) Leukocytes \> 2,500/mcL b) Absolute neutrophil count \> 1,500/mcL c) Hemoglobin \> 9 g/dl d) Platelets \> 100,000/mcL e) Total bilirubin \< 1.5 mg/dl f) AST/ALT (SGOT/SGPT) \< 2.5 x ULN g) Alkaline Phosphatase \< 2.5 x ULN (unless bone metastasis is present in the absence of liver metastasis, in which case 3.0 x ULN would be acceptable. h) Serum magnesium \> 1.8 mg/dL i) Serum creatinine \< 1.5 mg/dl j) Serum potassium \> 3.8 mmol/L
7. Tumor negative for HER2 expression (0 or 1+ by IHC) or negative FISH testing
8. Patients must have a life expectancy of at least 12 weeks
9. Patients must be recovered from the effects of any prior surgery, radiotherapy, or other antineoplastic therapy
10. Patients must have \< Grade 2 pre-existing peripheral neuropathy per CTCAE
11. Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
12. Negative serum or urine β-hCG pregnancy test at screening, performed no more than 72 hours prior to treatment initiation; for patients of childbearing potential
13. Ability to understand and willingness to sign a written informed consent and HIPAA consent document
11. Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
12. Patients taking drugs leading to significant QT prolongation (See Appendix I: Medications That May Cause QTc Prolongation)
13. Concomitant use of CYP3A4 inhibitors (see Appendix II)
8. Patients with known HIV, hepatitis B or C (However, if patients have previously been treated for hepatitis B or C and have undetectable viral loads, they can be considered eligible for trial)
9. Pregnant or breast feeding. Refer to section 4.4 for further detail
10. Patients with any other medical or psychological condition deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
2. Patients may have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 as described in detail in section 11.0 or non-measurable tumors
3. Patients must have demonstrated metastatic disease and not received \>2 lines of systemic therapy for metastatic disease
4. Age \> 18 years
5. ECOG performance status 0, 1 or 2
6. Patients must have normal organ and marrow function as defined below: a) Leukocytes \> 2,500/mcL b) Absolute neutrophil count \> 1,500/mcL c) Hemoglobin \> 9 g/dl d) Platelets \> 100,000/mcL e) Total bilirubin \< 1.5 mg/dl f) AST/ALT (SGOT/SGPT) \< 2.5 x ULN g) Alkaline Phosphatase \< 2.5 x ULN (unless bone metastasis is present in the absence of liver metastasis, in which case 3.0 x ULN would be acceptable. h) Serum magnesium \> 1.8 mg/dL i) Serum creatinine \< 1.5 mg/dl j) Serum potassium \> 3.8 mmol/L
7. Tumor negative for HER2 expression (0 or 1+ by IHC) or negative FISH testing
8. Patients must have a life expectancy of at least 12 weeks
9. Patients must be recovered from the effects of any prior surgery, radiotherapy, or other antineoplastic therapy
10. Patients must have \< Grade 2 pre-existing peripheral neuropathy per CTCAE
11. Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
12. Negative serum or urine β-hCG pregnancy test at screening, performed no more than 72 hours prior to treatment initiation; for patients of childbearing potential
13. Ability to understand and willingness to sign a written informed consent and HIPAA consent document
11. Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
12. Patients taking drugs leading to significant QT prolongation (See Appendix I: Medications That May Cause QTc Prolongation)
13. Concomitant use of CYP3A4 inhibitors (see Appendix II)
8. Patients with known HIV, hepatitis B or C (However, if patients have previously been treated for hepatitis B or C and have undetectable viral loads, they can be considered eligible for trial)
9. Pregnant or breast feeding. Refer to section 4.4 for further detail
10. Patients with any other medical or psychological condition deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
Exclusion Criteria
1. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse event from agents administered more than 4 weeks earlier
2. Patients may not be receiving any other investigational agents or active anti-neoplastic therapies
3. Patients who have previously received romidepsin or Abraxane
4. Patients with untreated or uncontrolled brain metastases or leptomeningeal disease
5. Patients with known hypersensitivity to any of the components of romidepsin or who have had hypersensitivity reactions to paclitaxel
6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
7. Any known cardiac abnormalities such as:
1. Congenital long QT syndrome
2. QTc interval ≥ 500 milliseconds
3. Myocardial infarction within 6 months of C1D1. Subjects with a history of myocardial infarction between 6 and 12 months prior to C1D1 who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate
4. Other significant EKG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min)
5. Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV (see Appendix III) In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
6. An EKG recorded at screening showing evidence of cardiac ischemia (ST depression depression of ≥2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
7. Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions (see Appendix IV) and/or known ejection fraction \<40% by MUGA or \<50% by echocardiogram and/orMRI
8. A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)
9. Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
2. Patients may not be receiving any other investigational agents or active anti-neoplastic therapies
3. Patients who have previously received romidepsin or Abraxane
4. Patients with untreated or uncontrolled brain metastases or leptomeningeal disease
5. Patients with known hypersensitivity to any of the components of romidepsin or who have had hypersensitivity reactions to paclitaxel
6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
7. Any known cardiac abnormalities such as:
1. Congenital long QT syndrome
2. QTc interval ≥ 500 milliseconds
3. Myocardial infarction within 6 months of C1D1. Subjects with a history of myocardial infarction between 6 and 12 months prior to C1D1 who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate
4. Other significant EKG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min)
5. Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV (see Appendix III) In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
6. An EKG recorded at screening showing evidence of cardiac ischemia (ST depression depression of ≥2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
7. Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions (see Appendix IV) and/or known ejection fraction \<40% by MUGA or \<50% by echocardiogram and/orMRI
8. A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)
9. Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene Corporation
INDUSTRY
Sponsor Role
collaborator
Sidney Kimmel Cancer Center at Thomas Jefferson University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maysa Abu-khalaf, MD
Role: PRINCIPAL_INVESTIGATOR
Thomas Jefferson University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, Kirby RL, Clawson A, O'Shaughnessy JA. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007 Dec;7(11):850-6. doi: 10.3816/CBC.2007.n.049.
Reference Type
BACKGROUND
Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res Treat. 2011 Jan;125(1):55-63. doi: 10.1007/s10549-010-0825-z. Epub 2010 Mar 12.
Reference Type
BACKGROUND
Chang H, Rha SY, Jeung HC, Jung JJ, Kim TS, Kwon HJ, Kim BS, Chung HC. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. J Cancer Res Clin Oncol. 2010 Dec;136(12):1901-13. doi: 10.1007/s00432-010-0849-0. Epub 2010 Mar 9.
Reference Type
BACKGROUND
Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer. 1998 Jun 15;82(12):2366-72.
Reference Type
BACKGROUND
Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC Jr. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011 Oct 1;117(19):4424-38. doi: 10.1002/cncr.26073.
Reference Type
BACKGROUND
Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003;8(2):141-8. doi: 10.1634/theoncologist.8-2-141.
Reference Type
BACKGROUND
Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, Harris AL, van Marck EA. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003 Mar 10;88(5):718-25. doi: 10.1038/sj.bjc.6600807.
Reference Type
BACKGROUND
Desai N, Trieu V, Yao R, et al. Increased transport of nanoparticle albumin-bound paclitaxel (ABI-007) by endothelial gp60-mediated caveolar transcytosis: a pathway inhibited by Taxol. Eur J Cancer Suppl. 2004;2:182.
Reference Type
BACKGROUND
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009 Aug 1;27(22):3611-9. doi: 10.1200/JCO.2008.18.5397. Epub 2009 May 26.
Reference Type
BACKGROUND
Kim H, Kim SN, Park YS, Kim NH, Han JW, Lee HY, Kim YK. HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. Int J Oncol. 2011 Mar;38(3):807-12. doi: 10.3892/ijo.2010.879. Epub 2010 Dec 17.
Reference Type
BACKGROUND
Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, Komatsu A, Sakata H, Matsushita K, Ochiai T. Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells. Oncol Rep. 2007 Sep;18(3):585-92.
Reference Type
BACKGROUND
Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, Sinha R, Penson RT, Buhl-Jensen P, Crowley E, Tjornelund J, Knoblauch P, de Bono JS. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer. 2010 Jun 29;103(1):12-7. doi: 10.1038/sj.bjc.6605726. Epub 2010 Jun 15.
Reference Type
BACKGROUND
Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004 Oct 15;22(20):4067-74. doi: 10.1200/JCO.2004.04.068.
Reference Type
BACKGROUND
Modesitt SC, Sill M, Hoffman JS, Bender DP; Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 May;109(2):182-6. doi: 10.1016/j.ygyno.2008.01.009. Epub 2008 Mar 4.
Reference Type
BACKGROUND
Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res. 2006 Sep 1;12(17):5047-54. doi: 10.1158/1078-0432.CCR-05-2248.
Reference Type
BACKGROUND
Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005 Nov 1;23(31):7785-93. doi: 10.1200/JCO.2004.00.6148.
Reference Type
BACKGROUND
Rasheed W, Bishton M, Johnstone RW, Prince HM. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther. 2008 Mar;8(3):413-32. doi: 10.1586/14737140.8.3.413.
Reference Type
BACKGROUND
Robertson FM, Woodward WA, Pickei R, Ye Z, Bornmann W, Pal A, Peng Z, Hall CS, Cristofanilli M. Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. Cancer. 2010 Jun 1;116(11 Suppl):2760-7. doi: 10.1002/cncr.25176.
Reference Type
BACKGROUND
Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol. 2005 Feb 15;69(4):603-16. doi: 10.1016/j.bcp.2004.11.008. Epub 2004 Dec 23.
Reference Type
BACKGROUND
ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665-85. doi: 10.2165/00003088-200342070-00005.
Reference Type
BACKGROUND
Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem. 1994 Sep;58(9):1579-83. doi: 10.1271/bbb.58.1579.
Reference Type
BACKGROUND
Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat. 2005 Oct;93(3):237-46. doi: 10.1007/s10549-005-5157-z.
Reference Type
BACKGROUND
Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, Lu Z, Bast RC Jr, Feng Y, Yu Y. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer. 2011 Jan 19;11:22. doi: 10.1186/1471-2407-11-22.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.JeffersonHospital.org
Thomas Jefferson University Hospitals
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-035
Identifier Type: OTHER
Identifier Source: secondary_id
JT 2987
Identifier Type: OTHER
Identifier Source: secondary_id
13C.387
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
NCT00251472
COMPLETED
PHASE2
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
NCT00472693
COMPLETED
PHASE2
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
NCT01307891
COMPLETED
PHASE2
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
NCT00093145
COMPLETED
PHASE2
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
NCT01207102
TERMINATED
PHASE2
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT05660083
RECRUITING
PHASE2
A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
NCT03988114
WITHDRAWN
PHASE4
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
NCT02308020
COMPLETED
PHASE2
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
NCT02688088
COMPLETED
PHASE1
Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
NCT00031876
COMPLETED
PHASE1/PHASE2
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
NCT01349088
WITHDRAWN
PHASE1/PHASE2
T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer
NCT04351230
WITHDRAWN
PHASE2
Non-interventional Study With Nab-Paclitaxel (Abraxane®)
NCT01689610
COMPLETED
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
NCT00046514
COMPLETED
PHASE2
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
NCT00096109
TERMINATED
PHASE2
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
NCT00684983
COMPLETED
PHASE2
Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer
NCT00003539
COMPLETED
PHASE2
Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer
NCT00265733
COMPLETED
PHASE2
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT04703920
COMPLETED
PHASE1
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
NCT03101748
TERMINATED
PHASE1/PHASE2
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
NCT02120417
TERMINATED
PHASE2
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
NCT04134884
COMPLETED
PHASE1
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
NCT02102490
COMPLETED
PHASE2
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
NCT03193853
COMPLETED
PHASE2
FR901228 in Treating Patients With Metastatic Breast Cancer
NCT00098397
COMPLETED
PHASE2